AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Overhead view of senior Asian woman feeling sick, taking medicines in hand with a glass of water at home. Elderly and healthcare concept

Business

Rani is Opening Doors in Biosimilars, Challenging Humira and Others

San Jose-based Rani Therapeutics reported its fourth quarter and full-year 2021 financial results. The company hit major milestones this year, including the recent launch of the RaniPill High Capacity,

March 31, 2022

3 min read

Hannah Chudleigh

Policy

Teva, Allergan Reach Opioid Settlement Agreement with Rhode Island

Teva Pharmaceuticals and AbbVie will pay the state of Rhode Island a combined $28.5 million to settle opioid-related claims against the companies.

March 22, 2022

3 min read

Alex Keown

SKYRIZI is the new option for psoriatic arthritis.

Drug Development

AbbVie’s Rinvoq Breaks into Gastroenterology Space with UC Approval

This is the first approval for the drug in gastroenterology and was based on data from three Phase III trials.

March 17, 2022

2 min read

Mark Terry

Policy

Novartis, Lilly, Merck and More Halt Business Operations in Russia

More pharmaceutical companies are joining to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine.

March 16, 2022

3 min read

Alex Keown

Pictured: A corporate building overlooking a freew

Business

Frazier Life Sciences Commits $1B to Nurturing New Biotech Companies

In total, FSI XI has netted over $987 million in commitments to drive the success of Frazier’s ongoing investment strategy.

March 16, 2022

2 min read

Jazmine Colatriano

Drug Development

Clinical Catch-Up: Pfizer’s Paxlovid, Immunome Set and Gilead’s Trodelvy

Across a range of indications, COVID-19-related and non-COVID-19-related, there was plenty of clinical trial news last week.

March 13, 2022

8 min read

Mark Terry

Business

Harpoon to Discontinue Once Promising Treatment for Prostate Cancer

Harpoon Therapeutics, Inc. has unfortunately announced that it will move to discontinue one of its promising T cell engager biologics, HPN424.

March 11, 2022

2 min read

Jazmine Colatriano

Business

AbbVie, Richter Unite to Target Complex Neuropsychiatric Conditions

The two companies will work closely to harness the abilities of dopamine receptor modulators to help patients living with complex neuropsychiatric conditions.

March 11, 2022

2 min read

Vanessa Doctor, RN

Drug Development

AbbVie Prepares to Seek Supplemental Approval for Migraine Treatment

AbbVie announced Qulipta hit the mark in its Phase III study by reducing mean monthly migraine days compared to placebo. Learn more about this migraine treatment here.

March 10, 2022

3 min read

Alex Keown

JOBS